Cat. No.: HY-N0780

Copy Link Print Information

Isoalantolactone

(Synonyms: (+)-Isoalantolactone; Isohelenin)

6 Cited Publications

Customer Review

Based on 6 publication(s) in Google Scholar

Isoalantolactone is an apoptosis inducer, which also acts as an alkylating agent.

For research use only. We do not sell to patients.

Purity: 99.99%
CAS No.: 470-17-7
Formula: C₁₅H₂₀O₂
Molecular Weight:232.32

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Isoalantolactone Chemical Structure

CAS No.: 470-17-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Isoalantolactone is an apoptosis inducer, which also acts as an alkylating agent.

IC₅₀ & Target

Apoptosis^[1]

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.38 μg/mL Compound: 8	Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
A549	IC₅₀	0.6 μM Compound: 21	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	10.1039/C2MD20172K
HeLa	IC₅₀	8.15 μM Compound: Isoalantolactone	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 31784199]
HepG2	IC₅₀	1.77 μg/mL Compound: 8	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
HT-1080	IC₅₀	0.795 μg/mL Compound: 8	Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
HUVEC	IC₅₀	2.5 μg/mL Compound: 8	Antiproliferative activity against human HUVEC assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay Antiproliferative activity against human HUVEC assessed as inhibition of cell proliferation after 72 hrs by CCK8 assay	[PMID: 23451797]
K562	IC₅₀	1.2 μM Compound: 2	In vitro inhibitory activity against K562 human leukemia cell line In vitro inhibitory activity against K562 human leukemia cell line	[PMID: 11212128]
K562	IC₅₀	1.2 μM Compound: 21	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	10.1039/C2MD20172K
MCF7	IC₅₀	0.6 μM Compound: 21	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	10.1039/C2MD20172K
NCI-H520	IC₅₀	0.9 μM Compound: 21	Antiproliferative activity against human NCI-H520 cells Antiproliferative activity against human NCI-H520 cells	10.1039/C2MD20172K
P388	IC₅₀	0.4 μM Compound: 21	Antiproliferative activity against mouse P388 cells Antiproliferative activity against mouse P388 cells	10.1039/C2MD20172K
Platelet	IC₅₀	>516.2 μM Compound: 32	Inhibition of serotonin release in bovine platelets Inhibition of serotonin release in bovine platelets	[PMID: 18271521]
Platelet	IC₅₀	>516.5 μM Compound: Isoalantolactone	Antimigraine activity in bovine citreated platelet assessed as inhibition of [14C]serotonin release after 6 mins by scintillation counting Antimigraine activity in bovine citreated platelet assessed as inhibition of [14C]serotonin release after 6 mins by scintillation counting	[PMID: 1431933]

In Vitro

Isoalantolactone exhibits good cytotoxic activity against the K562 human leukaemia cell line (IC₅₀=1.2 μM) ^[1]. The cytotoxic effect of Isoalantolactone on pancreatic carcinoma is evaluated using PANC-1, BxPC3 and HPAC cell lines. Treatment with Isoalantolactone for 24 h inhibits PANC-1 cell growth in a dose-dependent manner. The inhibition rate is above 90% at 80 μM and the concentration to achieve 50% growth inhibition (IC₅₀) is 40 μM. A similar trend in loss of cell viability is observed in BxPC3 and HPAC cells on Isoalantolactone treatment with IC₅₀ values 43 and 48 μM respectively. Pretreatment with 3 mM N-Acetyl Cysteine (NAC), a specific ROS scavenger, restores the viability of cells indicating that Isoalantolactone exerts cytotoxic effect on cell viability through ROS generation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The acute and chronic toxic effects of Isoalantolactone in CD1 mice are assessed by measuring the changes in body weight, blood biochemistry and histopathology of liver and kidneys in comparison with control groups. Isoalantolactone is well tolerated by mice and no mortality or any sign of pharmacotoxicity are found at a dose of 100 mg/kg during both experimental periods (7 & 30 days). Body weight gains and food consumption are comparable for control and treated mice during both experimental periods and there were no drug-related changes in histopathological and blood biochemistry parameters. The histopathological changes in liver and kidneys are assessed using hematoxylin and eosin staining and correlated with liver and renal function biomarkers. No obvious morphological changes are observed in liver and kidney structures of control and treatment groups. There is a slight increase in serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level of treatment group at dose day 7 but this increase is not significantly different (P<0.05) from control group. A significant increase in total bilirubin (TBIL) concentration is found in treatment group (1.43±0.26 vs 0.76±0.12 in control, P<0.05) at dose day 7. Similarly the changes in renal function biomarkers are not significantly different (P<0.05) in the serum of control and treatment groups at dose day 7. The concentration of creatinine (Cr) slightly increases whereas concentration of blood urea nitrogen (BUN) slightly decreases in treatment group. The serum level of AST, ALT, TBIL and BUN slightly decreases when mice are injected with Isoalantolactone at a dose of 100 mg/kg for 30 days^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 470-17-7
Appearance Solid
Molecular Weight 232.32
Formula C₁₅H₂₀O₂
Color White to off-white
SMILES

O=C(O[C@@](C[C@@]1(C)CCC2)([H])[C@]3([H])C[C@@]1([H])C2=C)C3=C
Synonyms

(+)-Isoalantolactone; Isohelenin
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All Cell Proliferation/Viability AssayApoptosis AnalysisWBIFRT-PCR

Sort by:

Journal Impact Factor

Pharmacol Res

Cardamonin retards progression of autosomal dominant polycystic kidney disease via inhibiting renal cyst growth and interstitial fibrosis. [Abstract]

2020 May;155:104751. PMID: 32151678
J Ethnopharmacol

Xihuang pill suppressed primary liver cancer growth by downregulation of AFP and YAP signaling. [Abstract]

2025 Apr 26:348:119891. PMID: 40294663
Biochem Pharmacol

Isoalantolactone targets NLRP3 to disrupt NLRP3-NEK7 interaction and suppress inflammasome activation. [Abstract]

2026 Jun 13;251(Pt 2):118165. PMID: 42288193
Cell Mol Life Sci

Contact-dependent signaling triggers tumor-like proliferation of CCM3 knockout endothelial cells in co-culture with wild-type cells. [Abstract]

2022 Jun 4;79(6):340. PMID: 35661927
Transl Oncol

Regulation of Hippo-YAP signaling axis by Isoalantolactone suppresses tumor progression in cholangiocarcinoma. [Abstract]

2024 May 25:46:101971. PMID: 38797019

Isoalantolactone purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2024 May 25:46:101971. [Abstract]

The effect of IALT on cell proliferation was measured using MTT assay. SNU478 cells were treated with different concentrations of Isoalantolactone (IALT) (0, 0.5, 1, 1.5, 2, 2.5 μM) for 48 h.

Isoalantolactone purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2024 May 25:46:101971. [Abstract]

Cell apoptosis distributions were determined via flow cytometry using Annexin V/PI staining after 0, 5, and 10 μM of Isoalantolactone (IALT) treatment for 48 h.

Isoalantolactone purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2024 May 25:46:101971. [Abstract]

SNU478 cells were treated with 0, 5, and 10 μM of Isoalantolactone (IALT) for 72 h. Cell lysates were immunoblotted.

Isoalantolactone purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2024 May 25:46:101971. [Abstract]

SNU478 cells were treated with 2 μM Isoalantolactone (IALT) for 3 h and stained with YAP (green) and DAPI (blue).

Isoalantolactone purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2024 May 25:46:101971. [Abstract]

The mRNA levels of CYR61 and CTGF were determined via qRT-PCR in SNU478 cells treated with 0, 5, and 10 μM of Isoalantolactone (IALT) for 12 h.
Plants

Targeted Screening and Quantification of Characteristic Sesquiterpene Lactones in Ambrosia artemisiifolia L. at Different Growth Stages. [Abstract]

2024 Jul 25;13(15):2053. PMID: 39124171

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (430.44 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.3044 mL

21.5220 mL

43.0441 mL

5 mM

0.8609 mL

4.3044 mL

8.6088 mL

10 mM

0.4304 mL

2.1522 mL

4.3044 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (10.76 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Cell viability is assessed by MTT assay. Briefly PANC-1, BxPC3, and HPAC cells are treated with DMSO or Isoalantolactone (5, 10, 20, 40, 80 and 100 μM) in the presence or absence of 3 mM NAC for 24 h. Following treatment, the MTT reagent is added (500 µg/mL) and cells are further incubated at 37°C for 4 h. Subsequently 150 μL DMSO is added to dissolve farmazan crystals and absorbance is measured at 570 nm in a microplate reader. The percentage of cell viability is calculated^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Mice^[2]
In vivo studies for acute and chronic toxicity are conducted on 10-12 week old CD1 mice weighing 27-30 g. The mice are maintained in a specific pathogen-free grade animal facility on a 12-h light/dark cycles at 25±2°C. Mice are randomly divided into four groups. Group A (n=4) administered with 50 µL DMSO intraperitonially for 7 days; Group B (n=4) administered with Isoalantolactone (100 mg/kg body weight) in 50 µL DMSO intraperitonially for 7 days; Group C (n=4) administered with 50 µL DMSO for 30 days and Group D (n=4) administered with Isoalantolactone (100 mg/kg body weight) in 50 µL DMSO intraperitonially for 30 days. At the first and last day of the experiments, the body weight of each mouse is measured. At the end of experiments (at dose day 7 for acute toxicity & dose day 30 for chronic toxicity), mice are anesthetized using Pentobarbital sodium (50 mg/kg ip), blood is collected via cardiac puncture, allowed to clot for 10 min and centrifuge at 1000×g for 10 min at room temperature. Serum is separated and stored at -20°C until analysis. The liver and kidneys are excised and processed for hematoxylin and eosin staining followed established procedures.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Lawrence NJ, et al. Cytotoxic Michael-type amine adducts of alpha-methylene lactones alantolactone and isoalantolactone. Bioorg Med Chem Lett. 2001 Feb 12;11(3):429-31. [Content Brief]

[2]. Khan M, et al. Isoalantolactone induces reactive oxygen species mediated apoptosis in pancreatic carcinoma PANC-1 cells. Int J Biol Sci. 2012;8(4):533-47. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.3044 mL	21.5220 mL	43.0441 mL	107.6102 mL
	5 mM	0.8609 mL	4.3044 mL	8.6088 mL	21.5220 mL
	10 mM	0.4304 mL	2.1522 mL	4.3044 mL	10.7610 mL
	15 mM	0.2870 mL	1.4348 mL	2.8696 mL	7.1740 mL
	20 mM	0.2152 mL	1.0761 mL	2.1522 mL	5.3805 mL
	25 mM	0.1722 mL	0.8609 mL	1.7218 mL	4.3044 mL
	30 mM	0.1435 mL	0.7174 mL	1.4348 mL	3.5870 mL
	40 mM	0.1076 mL	0.5381 mL	1.0761 mL	2.6903 mL
	50 mM	0.0861 mL	0.4304 mL	0.8609 mL	2.1522 mL
	60 mM	0.0717 mL	0.3587 mL	0.7174 mL	1.7935 mL
	80 mM	0.0538 mL	0.2690 mL	0.5381 mL	1.3451 mL
	100 mM	0.0430 mL	0.2152 mL	0.4304 mL	1.0761 mL

Keywords

Isoalantolactone

6 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Isoalantolactone

Anti-Infection Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Antibacterial Compound Library

Terpenoids Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Isoalantolactone

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (6)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Isoalantolactone Related Classifications

HY-N0780 Related Classifications